1. Target-vessel failure was significantly lower in the ultrasound-guided group than the angiography-guided group. 2. There was no significant difference...

1. Patients in the PCI group reported significantly lower rates of cardiac death, revascularization, and hospitalization than those in the...

1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse...

1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer...

1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who...

1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature...

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly...

1. RSV-related ALRI incidence was significantly higher among preterm infants than term infants. 2. This pattern for RSV hospitalizations remained...

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events...

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events...